Le Lézard
Classified in: Health, Business
Subjects: PER, VEN

410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors

DURHAM, N.C., Oct. 22, 2019 /PRNewswire/ -- 410 Medical, Inc., a medical device company developing innovative technologies for critical care, announced today it has closed on a Series A financing of $8 million led by Hatteras Venture Partners, with participation from OSF Healthcare and existing investors including Sovereign's Capital. 410's lead product, LifeFlow®, is designed to enable clinicians to more effectively and efficiently deliver fluids to critically ill patients.  

410 Medical, Inc., a medical device company focused on developing innovative technologies for the resuscitation of critically ill patients. (PRNewsfoto/410 Medical, Inc.)

"LifeFlow has been designed to deliver fluids up to 10 times faster than traditional methods, which can be particularly impactful for patients suffering from sepsis, shock and trauma, who are at higher risk of organ failure and death," said Kyle Chenet, Chief Executive Officer at 410 Medical. "This new funding will be instrumental in expanding commercialization of LifeFlow in hospital and pre-hospital environments nationwide, ensuring that more patients receive time-sensitive fluid resuscitation."

Severe sepsis affects over 1 million adults and children each year in the US. It is the most frequent cause of death in hospitalized patients and the leading killer of children worldwide. Early, rapid delivery of fluid is a life-saving therapy, yet with existing methods providers often fail to achieve published fluid delivery guidelines.  Since FDA clearance in 2016, LifeFlow has seen increasing adoption at leading healthcare systems throughout the U.S., including Cincinnati Children's Hospital Medical Center, Children's Hospital Colorado, and WakeMed Health & Hospitals.

"We are thrilled to support the vision of 410 Medical's founders, to ensure LifeFlow can be in the hands of any clinician needing to provide rapid fluids for a critically ill patient," said Jeff Terrell, Partner at Hatteras. Mr. Terrell will be joining the 410 Medical Board of Directors along with Stan Lynall, Vice President of Venture Investments at OSF Ventures. OSF Ventures is the venture capital arm of OSF HealthCare, an Illinois-based health system with 124 locations and 13 hospitals.

About 410 Medical, Inc.
Founded in 2013, 410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. 410 Medical's first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening illnesses such as sepsis and shock. LifeFlow was cleared by the FDA for human use in 2016. For more information, visit www.410medical.com.

About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Durham, N.C., with a focus on seed and early stage opportunities across the health care continuum from transformative therapies to disruptive technologies. The firm has six funds and over $550 million in capital commitments under management. Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation. To learn more about Hatteras Venture Partners, please visit www.hatterasvp.com.

About OSF Ventures
OSF Ventures specializes in venture optimization, partnering financially and operationally in companies that improve patient outcomes and reduce costs to health care systems. OSF Ventures is a division of OSF HealthCare. More at www.osfventures.org.

SOURCE 410 Medical, Inc.

These press releases may also interest you

at 04:45
87% of shoppers search for products online. ECommerceCompanies.com, a B2B marketplace connecting brands with eCommerce designers and developers, identified the best eCommerce marketing companies that help brands boost their online visibility and...

at 04:30
FinVolution Group ("FinVolution", or the "Company") , a leading fintech platform in China, today announced that it will report its first quarter 2020 unaudited financial results, on wednesday, May 27, 2020, before the open of U.S. markets....

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 03:38
Guide Infrared ("the Company"), a leading Chinese manufacturer of infrared thermal imaging systems based in China Optical Valley, has released its first-quarter earnings snapshot. In the first quarter, Guide Infrared is expected to book a profit of...

at 03:30
Rokmaster Resources Corp. ("Rokmaster" or the "Company") is pleased to announce that it has closed the first tranche of the non-brokered financing (the "Financing") involving the issuance of flow-through units (the "Flow-Through Units") and...

at 03:10
Champignon Brands Inc. ("Champignon" or the "Company") , a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business...

News published on 22 october 2019 at 08:15 and distributed by: